1	Germline mutations in young-onset sporadic pituitary macroadenomas: a multigene panel
2	analysis
3	
4	Leonor M. Gaspar ¹ , Catarina I. Gonçalves ¹ , Ema L. Nobre ² , Fernando Fonseca ³ , Cláudia Amaral ⁴ ,
5	João S. Duarte ⁵ , Luísa Raimundo ⁶ , Catarina Saraiva ⁵ , Luísa Cortez ³ , Olinda Marques ⁷ , Manuel C.
6	Lemos ^{1*}
7	
8	¹ CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal
9	² Serviço de Endocrinologia, Diabetes e Metabolismo, Hospital de Santa Maria, Unidade Local de
10	Saúde Santa Maria, Lisboa, Portugal
11	³ Serviço de Endocrinologia, Hospital de Curry Cabral, Unidade Local de Saúde São José, Lisboa,
12	Portugal
13	⁴ Serviço de Endocrinologia, Hospital de Santo António, Centro Hospitalar Universitário do Porto,
14	Porto, Portugal
15	⁵ Serviço de Endocrinologia, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisboa,
16	Portugal
17	⁶ Serviço de Endocrinologia e Diabetes, Hospital Garcia de Orta, Almada, Portugal
18	⁷ Serviço de Endocrinologia, Hospital de Braga, Braga, Portugal
19	
20	* Corresponding author:
21	Manuel C. Lemos
22	CICS-UBI, Health Sciences Research Centre
23	University of Beira Interior
24	6200-506 Covilhã, Portugal
25	Email: mclemos@fcsaude.ubi.pt
26	NOTER THE HEADING BOOLDING BEREARD THE has not been certified by peer review and should not be used to guide clinical practice.

- 27
- 28 Short title: Germline mutations in pituitary adenomas
- 29
- 30 Keywords: Pituitary adenoma; Genetics; Mutation
- 31
- 32 Word count 2701 (excluding abstract, references, table, figure legend, and supplemental
- 33 material).
- 34

35 Abstract

36

Objective: Mutations in several genes have been associated with familial forms of pituitary adenomas. Sporadic pituitary adenomas (i.e. with no family history or coexistent endocrine tumours) are also occasionally found to result from germline mutations in these genes, especially in young patients with larger tumours. The aim of this study was to determine the frequency of germline mutations in patients with young-onset sporadic pituitary macroadenomas.

43 Methods: A cohort of 225 Portuguese patients with sporadic pituitary macroadenomas 44 diagnosed before the age of 40 years was studied by whole exome sequencing (WES) followed 45 by the analysis of a virtual panel of 29 genes that have been associated with predisposition to 46 pituitary adenomas.

Results: Pathogenic and likely pathogenic variants were identified in 16 (7.1%) of patients. The
affected genes were *AIP* (n=4), *PMS2* (n=4), *MEN1* (n=2), *VHL* (n=2), *CDH23* (n=1), *MSH2* (n=1), *SDHB* (n=1), and *TP53* (n=1). In patients diagnosed under the ages of 30 and 18 years, the
frequency of mutations increased to 9.0% and 12.0%, respectively.

51 **Conclusion**: This is so far the largest multigene analysis of patients with young-onset sporadic 52 pituitary macroadenomas. We confirmed the *AIP* as the most frequently involved gene, but also 53 uncovered rarer genetic causes of pituitary adenomas, including the first independent 54 confirmation of a role of the *CDH23* gene. The results may contribute to a better understanding 55 of the genetic landscape of these tumours and help to decide which genes to include in the 56 genetic screening of patients with young-onset pituitary macroadenomas.

58 Introduction

59 Most pituitary adenomas occur sporadically and are often attributed to acquired somatic and 60 epigenetic mutations (1). However, a subset of cases arises within a familial context, either as 61 part of syndromic diseases or as familial isolated pituitary adenomas (FIPA), which are caused 62 by pathogenic germline mutations (2). Tumours within familial settings tend to be more 63 aggressive, manifesting at a younger age, with larger sizes, increased invasiveness, and resistance to standard treatments (3). An expanding list of genes, including AIP, CABLES1, 64 CDH23, CDKN1A, CDKN1B, CDKN2B, CDKN2C, DICER1, GNAS, GPR101, MAX, MEN1, MLH1, 65 66 MSH2, MSH6, NF1, PMS2, PRKACA, PRKACB, PRKAR1A, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, 67 TP53, USP8, and VHL, has been identified with germline or mosaic mutations predisposing individuals to pituitary adenomas (4-6). Identifying these genetic alterations is not only crucial 68 69 for accurate diagnosis and personalized treatment, but also provides valuable insights into the 70 molecular pathways disrupted in these tumours (7).

While sporadic cases traditionally lack a clear hereditary component, several studies have shown that a variable proportion of these cases harbour germline mutations (8). The most extensively studied gene is *AIP*, which was first associated with FIPA (9), but later found to be mutated in many apparently sporadic cases, particularly among patients of younger ages and with larger tumours (10).

We recently screened a cohort of patients diagnosed with young-onset sporadic pituitary macroadenomas for *AIP* mutations (11). This revealed the presence of *AIP* mutations in 1.8%, 3.4% and 5.0% of patients diagnosed under the ages of 40, 30 and 18 years, respectively (11). Building upon this, we have now employed next-generation sequencing to expand the genetic screening to all genes with germline mutations that have so far been associated with familial isolated or syndromic pituitary adenomas.

82

83 Materials and Methods

84 Subjects

This was a follow-up study of a Portuguese multicentre cohort that had been previously studied 85 86 by conventional (Sanger) sequencing of the AIP gene (11). A total of 225 patients were available 87 for this study. Inclusion criteria were patients with macroadenomas (tumour greater diameter \geq 1 cm) diagnosed under the age of 40 years. Exclusion criteria were patients with a family history 88 89 of pituitary adenomas (i.e. affected first or second degree family member) or with evidence of 90 a syndromic form of pituitary adenoma. Mean age (± standard deviation) at diagnosis was 29.1 91 ± 7.3 years, 122 patients were under 30 years at diagnosis, and 25 patients were under 18 years 92 at diagnosis. Gender distribution was 116 (51.6%) females and 109 (48.4%) males. Tumour 93 classification was based on histological examination or, in the case of prolactinomas, by clinical, 94 hormonal and radiological examination. Eighty-one (36.0%) patients had prolactinomas, 62 95 (27.6%) had somatotrophinomas, 37 (16.4%) had non-functioning pituitary adenomas, 16 (7.1%) had mixed-secreting pituitary adenomas, 15 (6.7%) had corticotrophinomas, seven (3.1%) had 96 97 gonadotrophinomas, one (0.4%) had a thyrotrophinoma, and six (2.7%) had adenomas with 98 undetermined histology. The control population comprised 298 Portuguese individuals (50 99 healthy blood donors and 248 patients with unrelated disorders). The study was approved by 100 the Ethics Committee of the Faculty of Health Sciences, University of Beira Interior (Ref: CE-UBI-101 Pj-2018-027 and CE-FCS-2011-003) and written informed consent was obtained from all 102 subjects.

103

104 Whole exome sequencing (WES) and virtual gene panel

105 Genomic deoxyribonucleic acid (DNA) was extracted from the peripheral blood leukocytes of 106 each patient and used for WES analysis according to previously described methods (12). A virtual 107 gene panel was created, consisting of 29 genes in which germline or mosaic mutations have 108 been reported in patients with familial isolated or syndromic pituitary adenomas (4-6), namely 109 AIP (NM 003977.3), CABLES1 (NM 001100619.2), CDH23 (NM 022124.5), CDKN1A 110 (NM 078467.3), CDKN1B (NM 004064.4), CDKN2B (NM 004936.4), CDKN2C (NM 001262.3), 111 DICER1 (NM_177438.3), GNAS (NM_000516.7), GPR101 (NM_054021.1), MAX (NM_002382), MEN1 (NM 130799.2), MLH1 (NM 000249.4), MSH2 (NM 000251.3), MSH6 (NM 000179.3), 112 113 NF1 (NM 000267.3), PMS2 (NM 000535.7), PRKACA (NM 002730.4), PRKACB (NM 182948.4), 114 PRKAR1A (NM 002734.5), RET (NM 020975.4), SDHA (NM 004168.3), SDHAF2 (NM 017841.2),

SDHB (NM_003000.3), SDHC (NM_003001.5), SDHD (NM_003002.3), TP53 (NM_000546.6),
USP8 (NM_005154.5), and VHL (NM_000551.3).

117

118 Interpretation of genetic variants

119 Genetic variants were filtered according to the following cumulative criteria: 1) Location in one 120 of the 29 genes previously implicated in pituitary adenomas; 2) Location in coding transcripts 121 used by the Human Genome Mutation Database (HGMD) (13); 3) Location in coding exons or up 122 to ten nucleotides adjacent to the coding exons; and 4) Population allele frequency less than 123 0.001 in the Genome Aggregation Database (gnomAD) and 1000 Genomes database (14). The 124 variants selected by these criteria were classified as benign (B), likely benign (LB), variant of 125 uncertain significance (VUS), likely pathogenic (LP) or pathogenic (P), according to American 126 College of Medical Genetics and Genomics (ACMG) criteria (15) and ClinGen recommendations 127 (16), using a web-based variant interpretation tool (Franklin by Genoox, reference hg19, https://franklin.genoox.com/, accessed on 30 March 2024). Filtered variants were screened in 128 129 an in-house database of 298 Portuguese control individuals to assess the possibility of variants 130 being population-specific common polymorphisms.

131

132 Validation of genetic variants by Sanger sequencing

133 Variants classified as pathogenic and likely pathogenic were confirmed by conventional Sanger

134 sequencing using a semi-automated DNA sequencer (STAB VIDA, Caparica, Portugal; and ABI

135 3730XL, Applied Biosystems; Thermo Fisher Scientific, Waltham, MA, USA).

137 Results

138 Rare sequence variants identified in the 29 analysed genes

A total of 154 (141 different) rare sequence variants (population allele frequency <0.001) were identified in 114 of the 225 patients. These variants were found in 25 of the 29 analysed genes and included three pathogenic, 13 likely pathogenic (11 different), 63 VUS (56 different), 64 likely benign (61 different) and 11 benign (10 different) (Supplemental Data 1). All rare sequence variants were identified in the heterozygous state.

144

145 Pathogenic and likely pathogenic variants

146 Pathogenic and likely pathogenic variants were identified in 16 (7.1%) patients with young-onset 147 sporadic pituitary macroadenomas. These consisted of four AIP gene mutations (previously 148 reported by us (11)) (p.Ser53ThrfsTer36, p.Arg81Ter, p.Leu115TrpfsTer41, and p.Glu246Ter), four PMS2 mutations (three patients with p.Asn335Ser, and one with p.Asp486GlufsTer109), 149 150 two MEN1 mutations (p.Trp183Ter, and p.Arg314 Asp315del), two VHL mutations 151 (p.Lys196Glu, and p.Glu52Ter), one CDH23 mutation (p.Glu2520Lys), one MSH2 mutation 152 (p.Arg524His), one SDHB mutation (p.Ile127Leu), and one TP53 mutation (p.Arg282Gln) (Table 153 1 and Figure 1).

154

155 Prevalence of mutations according to age of diagnosis

The prevalence of mutations was higher in patients with younger ages at diagnosis. The prevalence of mutations in patients diagnosed up until the age of 40, 30 and 18 years was 7.1% (16/225), 9.0% (11/122), and 12.0% (3/25), respectively.

159

160 Clinical characteristics of patients with mutations

161 The clinical characteristics of the 16 patients with identified mutations are presented in Table 1.

162 Patients had no personal history of additional tumours or other syndromic features at the time

163 of inclusion in the study. However, two patients with *MEN1* mutations were found to have

164 hyperparathyroidism during or after undertaking the genetic studies.

166 Discussion

167 Our analysis of 225 patients with young-onset sporadic pituitary macroadenomas showed that 168 16 (7.1%) patients had germline mutations in genes that are associated with familial forms of 169 pituitary adenomas. These mutations involved the *AIP* (1.8% of patients), *PMS2* (1.8%), *MEN1* 170 (0.9%), *VHL* (0.9%), *CDH23* (0.4%), *MSH2* (0.4%), *SDHB* (0.4%), and *TP53* (0.4%) genes.

171 The AIP gene is associated with FIPA (9), but has also been extensively studied in patients with 172 sporadic pituitary adenomas. The prevalence of AIP germline mutations in patients with 173 sporadic pituitary macroadenomas under the age of 40 has been reported to vary from 0% to 174 18% (11), depending of the country of origin, clinical characteristics of the cohort, and criteria 175 used for the classification of genetic variants. We found four (1.8%) patients with AIP mutations, 176 which were frameshift (p.Ser53ThrfsTer36, and p.Leu115TrpfsTer41) and nonsense (p.Arg81Ter, 177 and p.Glu246Ter) mutations expected to lead to a premature stop codon and to the formation 178 of a shorter protein or to nonsense-mediated decay (17). These AIP mutations were all found in 179 patients with GH-secreting adenomas, in agreement with the higher prevalence of AIP 180 mutations in this tumour type (18). These results confirm the results of our previous Sanger 181 sequencing of the AIP gene in this cohort of patients (11).

182 The PMS2 gene is associated with Lynch syndrome (19), which is characterised by the occurrence 183 of a variety of tumours that include colorectal, endometrial, ovarian and gastric cancers (20). 184 Although some cases of aggressive pituitary tumours have been reported in patients with Lynch 185 syndrome (21-23), the prevalence of PMS2 mutations in sporadic pituitary adenomas has never 186 been reported before. We found four (1.8%) patients with PMS2 mutations, with no other 187 apparent manifestations of Lynch syndrome. These consisted of a previously reported (24) 188 missense (p.Asn335Ser) mutation that was identified in three unrelated patients, diagnosed 189 with a somatotrophinoma, prolactinoma and non-functioning pituitary adenoma, and a novel 190 frameshift (p.Asp486GlufsTer109) mutation in a patient with a prolactinoma. Thus, our study 191 suggests that the PMS2 gene has a more important role in pituitary tumorigenesis than 192 previously acknowledged.

The *MEN1* gene is associated with the multiple endocrine neoplasia type 1 (MEN1) syndrome, which is characterised by the occurrence of parathyroid, pancreatic and pituitary tumours (25, 26). *MEN1* mutations are occasionally found in patients with pituitary adenomas without other MEN1 manifestations. A previous study identified *MEN1* mutations in 3.4% of patients with sporadic pituitary macroadenomas diagnosed before the age of 30 (27). Our study found two (0.9%) patients with *MEN1* mutations, which consisted of a previously reported (26) nonsense mutation (p.Trp183Ter) and a novel in-frame deletion (p.Arg314_Asp315del). Both patients had mixed GH-secreting adenomas. It is interesting to note that although there were no other apparent manifestations of the MEN1 syndrome at the time of the diagnosis of the pituitary adenoma, both patients were eventually found to have hyperparathyroidism during or after undertaking the genetic studies.

204 The VHL gene is associated with the Von Hippel–Lindau (VHL) syndrome, which is characterised 205 by tumours in several organs, such as retinal and central nervous system haemangioblastomas, 206 pheochromocytomas and clear-cell renal carcinomas (28). Pituitary adenomas have also been 207 described in patients with the VHL syndrome (29). However, the prevalence of VHL mutations 208 in sporadic pituitary adenomas has not been reported. We found two (0.9%) patients with VHL 209 mutations, with no other apparent manifestations of the VHL syndrome. These consisted of a 210 previously reported (30) nonsense (p.Glu52Ter) mutation in a patient with a prolactinoma and 211 a previously reported (31) missense (p.Lys196Glu) mutation in a patient with a 212 thyrotrophinoma. The latter mutation was previously reported in homozygosity in a patient with 213 autosomal recessive congenital erythrocytosis, but with no evidence of the VHL syndrome (31). 214 Therefore, it remains to be clarified if heterozygosity for this particular mutation, as found in our 215 patient, can cause the VHL syndrome.

216 The CDH23 gene is associated with the autosomal recessive Usher syndrome, which is 217 characterized by congenital deafness (32). However, a study by Zhang et al. (33) demonstrated 218 the presence of CDH23 heterozygous mutations in 33% and 12% of familial and isolated pituitary 219 adenomas, respectively. So far, these results have not been independently confirmed. 220 Furthermore, there have been no reports of a higher incidence of pituitary adenomas in patients 221 with Usher syndrome or in their heterozygous relatives. We found one (0.4%) patient with a GH-222 secreting adenoma and a previously reported (34) CDH23 missense mutation (p.Glu2520Lys). 223 Thus, our study represents the first independent confirmation of a role of CDH23 in the 224 development of pituitary adenomas.

The *MSH2* gene is also associated with Lynch syndrome (35, 36) and some affected patients have been reported to have aggressive pituitary adenomas (21-23). We found one (0.4%) patient with a previously reported (37) *MSH2* missense mutation (p.Arg524His), who had a prolactinoma with no other apparent manifestations of Lynch syndrome.

The *SDHB* gene is associated with paragangliomas and pheochromocytomas (38). Pituitary adenomas occasionally occur in association with these (3PA, Phaeochromocytoma, Paraganglioma and Pituitary adenoma association) (39). However, the prevalence of *SDHB*

mutations in sporadic pituitary adenomas is unknown. A French study of 263 patients with sporadic pituitary adenomas revealed two mutations in the *SDHA* gene, one in the *SDHC* gene, but none in *SDHB* (40). We found one (0.4%) patient with a previously reported (41) *SDHB* missense mutation (p.Ile127Leu), who had a prolactinoma without any other syndromic manifestations.

237 The TP53 gene is considered the most mutated tumour suppressor gene in human cancers (42). 238 Germline mutations in this gene are associated with the Li-Fraumeni syndrome, which 239 predisposes to soft tissue sarcomas, osteosarcoma, breast cancer, leukaemia, and 240 adrenocortical carcinoma (43). The role of the TP53 gene in pituitary adenomas is less clear. The 241 TP53 gene was included in our gene panel because a recent review (6) listed it as one of the 242 genes in which germline mutations are implicated in pituitary adenomas. However, although 243 somatic mutations in TP53 have been reported in pituitary adenomas (1), we found no reports 244 of germline mutations in patients with these tumours. Nevertheless, in our study, we found one 245 (0.4%) patient with a previously reported (44) TP53 germline missense mutation (p.Arg282Gln), 246 who had a corticotrophinoma without any other syndromic manifestations. Thus, our study 247 reports for the first time a TP53 germline pathogenic mutation in a patient with a pituitary 248 adenoma.

249 None of the patients included in our study had other coexistent tumours or syndromic features 250 or family history that would raise the suspicion of a germline mutation. The unexpected 251 identification of germline mutations in a subset of patients with sporadic tumours could have 252 several explanations. First, family history was self-reported by the patients and may have been 253 inaccurate or incomplete. Second, the lack of other affected family members could have been 254 due to incomplete penetrance of the mutation or to a *de novo* mutation in the patient. Third, 255 other syndromic manifestations could have been missed on clinical screening or absent due to 256 variable expression of the mutation. Importantly, our identification of patients with germline 257 mutations will improve their clinical management, allow the screening of additional syndromic 258 manifestations, and allow the identification of additional affected family members that can be 259 screened for the disorder (6).

Previous studies of sporadic pituitary adenomas have mainly focused on the *AIP* gene, as this is the most commonly mutated gene in such cases (8). Only three other studies performed gene panel analyses in patients with sporadic pituitary adenomas, but with a limited number of genes (\leq 9) that did not include for example the *VHL*, *PMS2* or *CDH23* genes (40, 45, 46). Nevertheless, these studies were able to identify pathogenic variants in 3.8% to 10% of patients with youngonset sporadic pituitary adenomas.

In our study, we analysed the largest panel of genes so far in patients with sporadic pituitary adenomas. We confirmed the *AIP* as the most frequently involved gene in these patients, but also uncovered rarer genetic causes of pituitary adenomas. Altogether, germline mutations were present in 7.1% of our patients diagnosed with sporadic macroadenomas under the age of 40 years. However, this proportion increased to 9.0% and 12.0%, in patients diagnosed under the ages of 30 and 18 years, respectively. This is in agreement with the general observation that tumours arising in younger ages are more likely to have a genetic cause.

- The existence of subsets of patients at higher risk of harbouring germline mutations has led to recommendations for *AIP* and *MEN1* mutation testing in patients with pituitary macroadenomas diagnosed under the age of 30 (10, 27) or 40 years (47). However, there are currently no recommendations for additional genetic testing of sporadic pituitary adenomas that have been shown to be *AIP* and *MEN1* mutation-negative. Our study suggests that testing such patients for a wider gene panel may uncover further cases of genetically-determined pituitary adenomas.
- Our study has some limitations. First, we did not look for copy number variants or mutations in non-coding genomic regions. Second, we did not look for mutations in other genes beyond those that have so far been associated with pituitary adenomas. Third, we found a large number of VUS, for which there is currently insufficient evidence for an association with the disorder, but that may need reclassification over time (48).
- In conclusion, we found a prevalence of 7.1% germline mutations in patients with young-onset pituitary macroadenomas. These include mutations in the *AIP*, *MEN1*, *MSH2*, *PMS2*, *SDHB*, *TP53* and *VHL* genes and the first independent confirmation of a mutation in the *CDH23* gene. Our results may contribute to a better understanding of the genetic landscape of these tumours and help to decide which genes to include in the genetic screening of patients with young-onset pituitary macroadenomas.
- 290

291 Supplementary data

- 292 Supplementary data 1. Rare sequence variants identified in patients with young-onset sporadic
- 293 pituitary macroadenomas.

294

295 Conflict of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

298

299 Funding

This research was funded by the Portuguese Foundation for Science and Technology (FCT, project grants PTDC/MEC-MET/29489/2017 and UIDB/00709/2020). LM Gaspar was the recipient of a PhD fellowship from FCT (SFRH/BD/147160/2019).

303

304 Acknowledgements

305 The authors are grateful to the following clinicians for collecting patient samples and clinical 306 data: Ana Agapito (Lisboa), Ana Monteiro (Braga), Ana Palha (Lisboa), Bernardo Pereira (Ponta 307 Delgada), Daniela Cavaco (Lisboa), Davide Carvalho (Porto), Hélder Simões (Lisboa), Henrique 308 Luiz (Almada), Inês Barros (Braga), Inês Damásio (Lisboa), Isabel Inácio (Porto), Joana Pereira 309 (Lisboa), João Anselmo (Ponta Delgada), Maria João Bugalho (Lisboa), Maria Manuel Silva 310 (Porto), Maria Salomé (Lisboa), Mariana Barbosa (Braga), Rita Santos (Lisboa), Sara Donato 311 (Lisboa), Sara Pinheiro (Lisboa), Sílvia Paredes (Braga), Teresa Martins (Coimbra), Teresa Rego 312 (Lisboa), Tiago Silva (Lisboa), and Valeriano Leite (Lisboa).

313

314 Data availability statement

The data from this study are available from the corresponding author upon reasonable request.

316

317 Author contribution statement

318 LM Gaspar and CI Gonçalves contributed to the acquisition, analysis and curation of genetic data,

319 and writing of the original draft of the manuscript. E Nobre, F Fonseca, C Amaral, J Sequeira

320 Duarte, L Raimundo, C Saraiva, L Cortez, and O Marques contributed to the recruitment and

- 321 clinical studies of the patients. MC Lemos contributed to the conceptualization, funding
- 322 acquisition, resources and supervision of the project. All authors contributed to reviewing and
- 323 editing and approved the final version of the manuscript.

325 References

326

Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, et al. Clinical Biology of
 the Pituitary Adenoma. Endocr Rev. 2022;43(6):1003-37.

De Sousa SMC, Lenders NF, Lamb LS, Inder WJ, McCormack A. Pituitary tumours:
 molecular and genetic aspects. J Endocrinol. 2023;257(3).

3. Armeni E, Grossman A. The Spectrum of Familial Pituitary Neuroendocrine Tumors.
 Endocr Pathol. 2023;34(1):57-78.

Vandeva S, Daly AF, Petrossians P, Zacharieva S, Beckers A. Somatic and germline
 mutations in the pathogenesis of pituitary adenomas. European journal of endocrinology.
 2019;181(6):R235-R54.

Shen AJJ, King J, Scott H, Colman P, Yates CJ. Insights into pituitary tumorigenesis: from
Sanger sequencing to next-generation sequencing and beyond. Expert review of endocrinology
& metabolism. 2019;14(6):399-418.

339 6. Coopmans EC, Korbonits M. Molecular genetic testing in the management of pituitary
340 disease. Clinical endocrinology. 2022;97(4):424-35.

Spada A, Mantovani G, Lania AG, Treppiedi D, Mangili F, Catalano R, et al. Pituitary
 Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
 Neuroendocrinology. 2022;112(1):15-33.

8. Iacovazzo D, Hernandez-Ramirez LC, Korbonits M. Sporadic pituitary adenomas: the role
 of germline mutations and recommendations for genetic screening. Expert review of
 endocrinology & metabolism. 2017;12(2):143-53.

Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, et al. Pituitary
 adenoma predisposition caused by germline mutations in the AIP gene. Science (New York, NY).
 2006;312(5777):1228-30.

Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, et al. High
 prevalence of AIP gene mutations following focused screening in young patients with sporadic
 pituitary macroadenomas. European journal of endocrinology. 2011;165(4):509-15.

Gaspar LM, Goncalves CI, Saraiva C, Cortez L, Amaral C, Nobre E, et al. Low frequency of
AIP mutations in patients with young-onset sporadic pituitary macroadenomas. J Endocrinol
Invest. 2023;46(11):2299-307.

Goncalves CI, Carrico J, Bastos M, Lemos MC. Disorder of Sex Development Due to 17Beta-Hydroxysteroid Dehydrogenase Type 3 Deficiency: A Case Report and Review of 70
Different HSD17B3 Mutations Reported in 239 Patients. Int J Mol Sci. 2022;23(17):10026.

13. Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The Human Gene
Mutation Database: towards a comprehensive repository of inherited mutation data for medical
research, genetic diagnosis and next-generation sequencing studies. Hum Genet.
2017;136(6):665-77.

14. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, et al. The mutational
constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):43443.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines
for the interpretation of sequence variants: a joint consensus recommendation of the American
College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Genetics in medicine : official journal of the American College of Medical Genetics.
2015;17(5):405-24.

16. Pejaver V, Byrne AB, Feng BJ, Pagel KA, Mooney SD, Karchin R, et al. Calibration of
computational tools for missense variant pathogenicity classification and ClinGen
recommendations for PP3/BP4 criteria. Am J Hum Genet. 2022;109(12):2163-77.

374 17. Karousis ED, Muhlemann O. The broader sense of nonsense. Trends Biochem Sci.
375 2022;47(11):921-35.

18. Caimari F, Hernandez-Ramirez LC, Dang MN, Gabrovska P, Iacovazzo D, Stals K, et al. Risk
category system to identify pituitary adenoma patients with AIP mutations. Journal of medical
genetics. 2018;55(4):254-60.

Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, et al. Mutations of
two PMS homologues in hereditary nonpolyposis colon cancer. Nature. 1994;371(6492):75-80.

381 20. Biller LH, Creedon SA, Klehm M, Yurgelun MB. Lynch Syndrome-Associated Cancers
382 Beyond Colorectal Cancer. Gastrointest Endosc Clin N Am. 2022;32(1):75-93.

Teuber J, Reinhardt A, Reuss D, Hahnel S, Unterberg A, Beynon C. Aggressive pituitary
adenoma in the context of Lynch syndrome: a case report and literature review on this rare
coincidence. Br J Neurosurg. 2021:1-6.

Loughrey PB, Baker G, Herron B, Cooke S, Iacovazzo D, Lindsay JR, et al. Invasive ACTHproducing pituitary gland neoplasm secondary to MSH2 mutation. Cancer Genet. 2021;256257:36-9.

Bengtsson D, Joost P, Aravidis C, Askmalm Stenmark M, Backman AS, Melin B, et al.
Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in
a Nationwide LS Cohort. The Journal of clinical endocrinology and metabolism.
2017;102(11):3928-32.

24. Castéra L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, et al. Next-generation
sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture
targeting multiple candidate genes. Eur J Hum Genet. 2014;22(11):1305-13.

25. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR,
et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (New York,
NY). 1997;276(5311):404-7.

26. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, et al. Identification of
the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum
Mol Genet. 1997;6(7):1177-83.

402 27. Cuny T, Pertuit M, Sahnoun-Fathallah M, Daly A, Occhi G, Odou MF, et al. Genetic
403 analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget
404 MEN1 genetic analysis. European journal of endocrinology. 2013;168(4):533-41.

Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von HippelLindau disease tumor suppressor gene. Science (New York, NY). 1993;260(5112):1317-20.

29. Denes J, Swords F, Rattenberry E, Stals K, Owens M, Cranston T, et al. Heterogeneous
genetic background of the association of pheochromocytoma/paraganglioma and pituitary

adenoma: results from a large patient cohort. The Journal of clinical endocrinology and
metabolism. 2015;100(3):E531-41.

411 30. Leonardi E, Martella M, Tosatto SC, Murgia A. Identification and in silico analysis of novel
412 von Hippel-Lindau (VHL) gene variants from a large population. Ann Hum Genet. 2011;75(4):483413 96.

414 31. Bento C, Almeida H, Maia TM, Relvas L, Oliveira AC, Rossi C, et al. Molecular study of 415 congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less 416 than half of the cases (Where is/are the missing gene(s)?). Eur J Haematol. 2013;91(4):361-8.

32. Bolz H, von Brederlow B, Ramirez A, Bryda EC, Kutsche K, Nothwang HG, et al. Mutation
of CDH23, encoding a new member of the cadherin gene family, causes Usher syndrome type
1D. Nat Genet. 2001;27(1):108-12.

33. Zhang Q, Peng C, Song J, Zhang Y, Chen J, Song Z, et al. Germline Mutations in CDH23,
Encoding Cadherin-Related 23, Are Associated with Both Familial and Sporadic Pituitary
Adenomas. Am J Hum Genet. 2017;100(5):817-23.

423 34. Cesca F, Bettella E, Polli R, Leonardi E, Aspromonte MC, Sicilian B, et al. Frequency of
424 Usher gene mutations in non-syndromic hearing loss: higher variability of the Usher phenotype.
425 J Hum Genet. 2020;65(10):855-64.

426 35. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al. The human
427 mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.
428 Cell. 1993;75(5):1027-38.

429 36. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al. Mutations of a
430 mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 1993;75(6):1215-25.

37. Paulo P, Maia S, Pinto C, Pinto P, Monteiro A, Peixoto A, et al. Targeted next generation
sequencing identifies functionally deleterious germline mutations in novel genes in earlyonset/familial prostate cancer. PLoS Genet. 2018;14(4):e1007355.

Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, et al. Gene mutations in the
succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and
to familial paraganglioma. Am J Hum Genet. 2001;69(1):49-54.

437 39. O'Toole SM, Denes J, Robledo M, Stratakis CA, Korbonits M. 15 YEARS OF
438 PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or
439 paragangliomas. Endocr Relat Cancer. 2015;22(4):T105-22.

440 40. Mougel G, Lagarde A, Albarel F, Essamet W, Luigi P, Mouly C, et al. Germinal defects of
441 SDHx genes in patients with isolated pituitary adenoma. European journal of endocrinology.
442 2020;183(4):369-79.

443 41. Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, et al. Succinate
444 dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol.
445 2012;188(6):2063-71.

446 42. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers.
447 Science (New York, NY). 1991;253(5015):49-53.

448 43. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH, et al. Germ line p53 449 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 450 (New York, NY). 1990;250(4985):1233-8.

44. Chompret A, Brugieres L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, et al. P53
germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer.
2000;82(12):1932-7.

45. De Sousa SMC, McCabe MJ, Wu K, Roscioli T, Gayevskiy V, Brook K, et al. Germline 455 variants in familial pituitary tumour syndrome genes are common in young patients and families 456 with additional endocrine tumours. European journal of endocrinology. 2017;176(5):635-44.

46. Martinez de LaPiscina I, Portillo Najera N, Rica I, Gaztambide S, Webb SM, Santos A, et
al. Clinical and genetic characteristics in patients under 30 years with sporadic pituitary
adenomas. European journal of endocrinology. 2021;185(4):485-96.

460 47. Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, et al. Germline AIP
461 mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center
462 cohort of 443 patients. The Journal of clinical endocrinology and metabolism. 2012;97(4):E663463 70.

464 48. Burke W, Parens E, Chung WK, Berger SM, Appelbaum PS. The Challenge of Genetic
465 Variants of Uncertain Clinical Significance : A Narrative Review. Ann Intern Med.
466 2022;175(7):994-1000.

467 49. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, et al. The role
468 of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary
469 adenomas. The Journal of clinical endocrinology and metabolism. 2008;93(6):2390-401.

470 50. Daly AF, Rostomyan L, Betea D, Bonneville JF, Villa C, Pellegata NS, et al. AIP-mutated
471 acromegaly resistant to first-generation somatostatin analogs: long-term control with
472 pasireotide LAR in two patients. Endocrine connections. 2019;8(4):367-77.

Gene (transcript)	Patient number (id)	Sex	Age at diagnosis (yr)	Type of adenoma (hormones produced)	Size of adenoma (mm)	Variant (nucleotide change, protein change) (a)	Effect	Allele frequency in GnomAD	Allele frequency in Portuguese controls	ACMG classification (criteria) (b)	Previous report
<i>AIP</i> (NM_003977.3)	1 (8215)	F	19-30	GH	20	c.158_165delGCCGGGCT, p.Ser53ThrfsTer36	Frameshift deletion	0	0	LP (PVS1, PM2)	(11)*
	2 (7879)	М	19-30	GH	26	c.241C>T, p.Arg81Ter	Nonsense	0	0	P (PVS1, PM2, PS4)	(49) (11)*
	3 (7329)	М	≤18	GH/PRL	14	c.343delC, p.Leu115TrpfsTer41	Frameshift deletion	0	0	LP (PVS1, PM2)	(50) (11)*
	4 (7632)	F	19-30	GH	28	c.736G>T, p.Glu246Ter	Nonsense	0	0	LP (PVS1, PM2)	(11)*
<i>CDH23</i> (NM_022124.5)	5 (7791)	М	19-30	GH	25	c.7558G>A, p.Glu2520Lys	Missense	0	0	LP (PS4, PM2, PP3, PP5)	(34)
<i>MEN1</i> (NM_130799.2)	6 (7850)	М	31-40	GH/PRL	60	c.548G>A, p.Trp183Ter	Nonsense	0	0	P (PVS1, PS4, PP5, PM2)	(26)
	7 (7971)	F	19-30	GH/PRL/TSH	40	c.940_945delCGGGAT, p.Arg314_Asp315del	In-frame deletion	0	0	LP (PM1, PM2, PM4)	None
<i>MSH2</i> (NM_000251.3)	8 (7642)	F	19-30	PRL	>10	c.1571G>A, p.Arg524His	Missense	0.000011	0	LP (PM2, PM5, PP3)	(37)
<i>PMS2</i> (NM_000535.7)	9 (8072)	М	31-40	GH	>10	c.1004A>G, p.Asn335Ser	Missense	0.000273	0	LP (PP3, PM2, BP6)	(24)
	10 (8094)	F	31-40	PRL	31	c.1004A>G, p.Asn335Ser	Missense	0.000273	0	LP (PP3, PM2, BP6)	(24)
	11 (8095)	F	31-40	Non- functioning	40	c.1004A>G, p.Asn335Ser	Missense	0.000273	0	LP (PP3, PM2, BP6)	(24)
	12 (7648)	М	19-30	PRL	>20	c.1458delC, p.Asp486GlufsTer109	Frameshift deletion	0	0	LP (PVS1, PM2)	None
<i>SDHB</i> (NM 003000.3)	13 (7887)	F	19-30	PRL	20	c.379A>C, p.lle127Leu	Missense	0.000004	0	LP (PM1, PM2, PM5, PP2, PP3)	(41)

Table 1. Clinical and genetic characteristics of 16 patients with pathogenic (P) and likely pathogenic (LP) variants.

<i>TP53</i> (NM_000546.0	14 (8079) 5)	F	31-40	ACTH	14	c.845G>A, p.Arg282GIn	Missense	0.000004	0	LP (BS3, PM2, PM5, PM1, PP3, PP5)	(44)
<i>VHL</i> (NM_000551.3	15 (6906) 3)	F	≤18	PRL	>10	c.154G>T, p.Glu52Ter	Nonsense	0.000018	0	LP (PVS1, PM2)	(30)
	16 (7792)	Μ	≤18	TSH	10	c.586A>G, p.Lys196Glu	Missense	0	0	P (PM1, PM2, PM3, PP2, PP3, PP5)	(31)

475 id, identification (anonymization code not known to anyone outside the research group); F, female; M, male; yr, years (presented as age range to protect patient privacy); FSH, follicle stimulating hormone; GH, growth

476 hormone; LH, luteinizing hormone; PRL, prolactin; TSH, thyroid stimulating hormone; mm, millimeters; GnomAD, Genome Aggregation Database (v2.1.1). (a) All variants were heterozygous. (b) American College of

477 Medical Genetics and Genomics (ACMG) classification of variants (P, pathogenic; LP, likely pathogenic) was based on the evidence for pathogenicity (very strong (PVS1), moderate (PM1-6), or supporting (PP1-5)).

478 479 ACMG classifications were based on the web-based variant interpretation tool Franklin (Genoox Ltd, https://franklin.genoox.com/), accessed on 30 March 2024. *Publication by the authors that included the same

patient.

Figure legend

Figure 1. Germline mutations identified in patients. The Sanger sequencing chromatograms are presented for each heterozygous mutation (indicated by an asterisk) and surrounding nucleotides.

